• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Essilor, HPO enter exclusive global license agreement

Article

Charenton le Pont, France-Essilor has signed an exclusive and global license agreement with High Performance Optics (HPO), that complements its existing patent and technologies portfolio. This license agreement will allow Essilor to continue to focus on products with correction and preventive benefits and to roll out its portfolio of products around the world.

The pact enables Essilor to strengthen its mission of reaching the 4.2 billion people worldwide who need vision correction.

As a result of the company’s R&D and innovation processes, Essilor currently has approximately 5,600 patents throughout the world that help extend its strategy.

Related Videos
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
Shelley Cutler, OD, FAAO, outlines her key takeaways from this year's IKA symposium
© 2024 MJH Life Sciences

All rights reserved.